GLP-1s, Weight & Blood Sugar News: What Headlines Claim vs. What the Data Really Shows.

That 93%–94% figure is real—it comes from the 176-week SURMOUNT-1 trial in the New England Journal of Medicine (PMID 39536238, N = 1,032)—but it is a Relative Risk Reduction (RRR). Here is the plain-English reality check: in the placebo group (people who took a dummy shot plus basic diet/exercise coaching for more than three years), only 13.3% developed Type 2 diabetes. That means 86.7% of people on placebo did NOT get diabetes anyway. Tirzepatide lowered that 13.3% rate down to 1.3%—which is a 12.1% Absolute Risk Reduction (ARR) and a Number Needed to Treat (NNT) of 9. Even more important: when the researchers stopped the injections for just 17 weeks at the end of the trial, weight and blood sugar immediately started bouncing back.

In a landmark randomized crossover trial published in Diabetes Care (PMID 23761134) and confirmed across 7 randomized trials in Sports Medicine (PMID 35268055), researchers tested older adults with prediabetes in a metabolic chamber . When participants took a 15-minute brisk walk 30 minutes after meals instead of one uninterrupted 45-minute morning walk, their 3-hour post-dinner glucose spike dropped by 22 to 35 mg/dL (p < 0.01) and their 24-hour average blood sugar improved significantly —all with the exact same total minutes of walking!